Erythropoietin protects tubular basement membrane by promoting bone marrow to release extracellular vesicles containing tPA-targeting miR-144.
In conclusion, our study provides the first evidence that EPO protects mouse renal TBM through promoting bone marrow cells to generate and secret miR-144, which in turn, is efficiently delivered into the mouse kidney via EVs to inhibit the activation of tPA/MMP9-mediated proteolytic network. This finding thus suggests that EPO, a hormone widely used to treat anemia in chronic kidney disease, is a potential therapeutic strategy for renal fibrosis.
PMID: 26469975 [PubMed - as supplied by publisher]
Source: Am J Physiol Renal P... - Category: Urology & Nephrology Authors: Zhou Y, Fang L, Yu Y, Niu J, Jiang L, Cao H, Sun Q, Zen K, Dai C, Yang J Tags: Am J Physiol Renal Physiol Source Type: research
More News: Anemia | Chronic Kidney Disease | Hormones | Study | Ureter and Renal Pelvis Cancer | Urology & Nephrology